Literature DB >> 15929665

Is patient's age a prognostic factor for follicular thyroid carcinoma in the TNM classification system?

Nikola Besic1, Janez Zgajnar, Marko Hocevar, Snjezana Frkovic-Grazio.   

Abstract

The knowledge of prognostic factors is essential for an optimal treatment of patients. The aim of our study was to find out if age is an independent prognostic factor for patients with follicular or Hürthle cell carcinoma. This retrospective study was carried out in 261 patients (median age, 62 years) with follicular or Hürthle cell thyroid carcinoma treated at our institute from 1972-2002. For all patients the follow-up was performed at our institute at least once per year. The data on gender and age of the patients, disease history, extent of disease, morphologic characteristics, mode of therapy, outcome, and survival were collected. Statistical correlation between possible prognostic factors and cause-specific survival was analyzed by univariate and Cox's multivariate survival analysis. The 10-year and 20-year survival of all 261 patients were 70% and 42%, respectively. Even 10 of 49 (20%) of our patients who were under 45 years of age (i.e., in stage II of the tumor, node, metastases [TNM] classification system) died of disease. Multivariate analysis showed that primary tumor size and distant metastases were independent prognostic factors for survival. Lymph node metastases as well as the age of patients were not found to be independent prognostic factors. Therefore, the patients with distant metastases or tumor stage T4 who are under 45 years of age cannot be considered to have favorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15929665     DOI: 10.1089/thy.2005.15.439

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  8 in total

Review 1.  Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

2.  Prognostic Impact of Further Treatments on Distant Metastasis in Patients With Minimally Invasive Follicular Thyroid Carcinoma: Verification Using Inverse Probability of Treatment Weighting.

Authors:  Yu-Mi Lee; Yi Ho Lee; Dong Eun Song; Won Bae Kim; Tae-Yon Sung; Jong Ho Yoon; Ki-Wook Chung; Suck Joon Hong
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

3.  Mortality-related factors in 1056 radioiodine-treated patients with well-differentiated thyroid cancer in southern Thailand.

Authors:  Tada Yipintsoi; Teerapon Premprabha; Alan Geater; Tanyaluck Thientunyakij; Suchitra Thongmak
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

4.  Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa
Journal:  Langenbecks Arch Surg       Date:  2014-02       Impact factor: 3.445

Review 5.  Lateral lymph node dissection guided by preoperative and intraoperative findings in differentiated thyroid carcinoma.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

6.  Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination.

Authors:  Yasuhiro Ito; Mitsuyoshi Hirokawa; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-07       Impact factor: 3.352

7.  Prognostic factors of papillary and follicular carcinomas in Japan based on data of kuma hospital.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  J Thyroid Res       Date:  2011-09-29

8.  Prognostic factors for disease-specific survival in 108 patients with Hürthle cell thyroid carcinoma: a single-institution experience.

Authors:  Rok Petric; Barbara Gazic; Nikola Besic
Journal:  BMC Cancer       Date:  2014-10-23       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.